Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

Early Phase 1

Completed

• Conditions: Pediatric Glaucoma

• Registration Number: NCT06983704
• Lead Sponsor: Benha University

Brief Summary

To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Detailed Description

Recurrent pediatric glaucoma following Ahmed Glaucoma Valve (AGV) implantation presents a therapeutic challenge. This study evaluates the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Study Timeline

• Status Verified: 2024-02
• Study Start: 2024-02-09
• Primary Completion: 2025-02-08
• Study Completion: 2025-02-15
• Study First Submitted: 2025-05-14
• Study First Submitted QC: 2025-05-14
• Last Update Submitted: 2025-05-14
• Study First Posted: 2025-05-21
• Last Update Posted: 2025-05-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• children under 12 years with previous AGV implantation for primary congenital glaucoma

Exclusion Criteria

• age >12 years, eyes with no light perception, and those with prior cyclodestructive procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
surgical success	for 12 months	IOP ≤ 21 mmHg and ≥ 5 mmHg without medications

Trial Locations

Locations (1)

Al-Azhar University; 🇪🇬 Cairo, Egypt